KR920700632A - 메일라드 반응저해제 - Google Patents

메일라드 반응저해제

Info

Publication number
KR920700632A
KR920700632A KR1019910701205A KR910701205A KR920700632A KR 920700632 A KR920700632 A KR 920700632A KR 1019910701205 A KR1019910701205 A KR 1019910701205A KR 910701205 A KR910701205 A KR 910701205A KR 920700632 A KR920700632 A KR 920700632A
Authority
KR
South Korea
Prior art keywords
formula
maillard reaction
reaction inhibitor
substance represented
inhibitor according
Prior art date
Application number
KR1019910701205A
Other languages
English (en)
Inventor
쥰 이노우에
Original Assignee
요시다 쇼오지
센쥬 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시다 쇼오지, 센쥬 세이야꾸 가부시끼가이샤 filed Critical 요시다 쇼오지
Publication of KR920700632A publication Critical patent/KR920700632A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

메일라드 반응저해제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 다음식
    [식중, X는 히드록실기 또는 니트로기를 나타낸다.]으로 표시되는 물질 또는 그 의약으로서 허용될수 있는 헤스테르를, 또는 그 물질 혹은 그 에스테르 의약으로서 허용될수있는 염을 함유하는 것을 특징으로 하는 메일라드 반응 제해제.
  2. 제1항에 있어서, 식(Ⅰ)로 표시되는 물질이 5-히드록시안트라닐산인 것을 특징으로 하는 메일라드 반응 저헤제.
  3. 제1항에 있어서, 식(Ⅰ)로 표시되는 물질이 3-히드록시안트라닐산인 것을 특징으로 하는 메일라드 반응 저헤제.
  4. 제1항에 있어서, 식(Ⅰ)로 표시되는 물질이 4-니트로안트라닐산인 것을 특징으로 하는 메일라드 반응 저헤제.
  5. 제1항에 있어서, 식(Ⅰ)로 표시되는 물질이 5-아미노살리살산인 것을 특징으로 하는 메일라드 반응 저헤제.
  6. 제1항에 있어서, 식(Ⅰ)로 표시되는 물질이 6-아미노살리살산인 것을 특징으로 하는 메일라드 반응 저헤제.
  7. 제1항에 있어서, 식(Ⅰ)로 표시되는 물질이 3-아미노살리살산인 것을 특징으로 하는 메일라드 반응 저헤제.
  8. 제1항에 있어서, 식(Ⅰ)로 표시되는 물질이 3-아미노-4-히드록시 안식향산인 것을 특징으로 하는 메일라드 반응 저헤제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910701205A 1990-02-19 1991-02-08 메일라드 반응저해제 KR920700632A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP90-39241 1990-02-19
JP3924190 1990-02-19
PCT/JP1991/000200 WO1991011997A1 (fr) 1990-02-19 1991-02-08 Inhibiteur de la reaction de maillard

Publications (1)

Publication Number Publication Date
KR920700632A true KR920700632A (ko) 1992-08-10

Family

ID=12547636

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701205A KR920700632A (ko) 1990-02-19 1991-02-08 메일라드 반응저해제

Country Status (7)

Country Link
EP (1) EP0474874B1 (ko)
KR (1) KR920700632A (ko)
AT (1) ATE129152T1 (ko)
CA (1) CA2049940C (ko)
DE (1) DE69113938T2 (ko)
ES (1) ES2078509T3 (ko)
WO (1) WO1991011997A1 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6228858B1 (en) 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6740668B1 (en) 1995-08-28 2004-05-25 Kansas University Medical Center Methods for inhibiting diabetic complications
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6730686B1 (en) 1995-09-12 2004-05-04 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
US6750209B1 (en) 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
GB9602444D0 (en) * 1996-02-07 1996-04-03 Chege Joseph Pharmaceutical compositions for the prevention or treatment of retrovirus infections
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
WO2000010606A1 (fr) 1998-08-24 2000-03-02 Kurokawa, Kiyoshi Medicaments de sedation de l'agression du carbonyle et des dialysats peritoneaux
AU1112500A (en) * 1998-10-14 2000-05-01 Kansas University Medical Center Research Institute, Inc. Methods for inhibiting diabetic complications
CA2347117C (en) * 1998-10-22 2006-01-24 University Of South Carolina Methods for inhibiting diabetic complications
WO2000059493A2 (en) * 1999-04-06 2000-10-12 Kansas University Medical Center Improved dialysis solutions and methods
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
JP4739705B2 (ja) * 2004-07-21 2011-08-03 ロート製薬株式会社 内服用組成物
BRPI0514827A (pt) * 2004-09-01 2008-06-24 Procter & Gamble composições compreendendo ácido 5-amino-2hidróxi- benzóico e açúcar redutor
JP5725599B2 (ja) * 2010-04-26 2015-05-27 池田食研株式会社 抗酸化性組成物の製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS567747A (en) * 1979-06-25 1981-01-27 May & Baker Ltd Acylaminobenzoic acid derivative

Also Published As

Publication number Publication date
EP0474874A1 (en) 1992-03-18
EP0474874A4 (en) 1992-08-19
ATE129152T1 (de) 1995-11-15
ES2078509T3 (es) 1995-12-16
EP0474874B1 (en) 1995-10-18
DE69113938T2 (de) 1996-04-11
CA2049940C (en) 1996-03-05
DE69113938D1 (de) 1995-11-23
WO1991011997A1 (fr) 1991-08-22

Similar Documents

Publication Publication Date Title
KR920700632A (ko) 메일라드 반응저해제
DK0604657T3 (da) Phosphonsyrediesterderivat
ATE127797T1 (de) Aminocoumaranderivate, ihre herstellung und verwendung.
DE68907583D1 (de) Verwendung von salicylsaeure-derivaten zur behandlung des hautalterns.
AR022203A1 (es) UN COMPUESTO, PROCESO PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE, Y UN PRODUCTO COMESTIBLE.
DE69500660D1 (de) Ophthalmische Zusammensetzung enthaltend ein 1,5-Benzoxathiepin-Derivat zur Behandlung von Glaukoma
DK0578511T3 (da) Spirooxathiolan-quinuclidinderivat til behandling af Sjögrens syndrom
ATE159514T1 (de) Substituierte aminsäure derivate verwendbar für die behandlung von arteriosclerosis
KR950700255A (ko) 피리딘카르복시이미드아미드 화합물 및 그 용도(pyridinecarboximidamide compounds and the use thereof)
KR910000158A (ko) 의약용 화합물 및 그것의 사용방법
KR880003626A (ko) 레트로비루스로 감염된 환자의 치료에 있어서의 2',3'-디디옥시사이티딘-2'-엔(2',3'-디디옥시-2',3'-디디하이드로사이티딘)의 사용법
MX9405660A (es) Nitrato esteres de 1-ariloxi-3-alquilamino-2-propanoles, utilizacion ycomposicion farmaceutica correspondiente.
IE43396L (en) Oxazolidinones
ATE100077T1 (de) 2-hydroxy-3-phenoxypropylaminoverbindungen.
PT90813A (pt) Processo de preparacao de derivados da fenotiazina e de composicoes farmaceuticas que os contem
ATE100439T1 (de) 2-(2-hydroxy-3-phenoxypropylamino)-ethoxybenzol derivate.
ES2196001T3 (es) Derivado de pirroloazepina.
ES463166A1 (es) Procedimiento para preparar ester isobutilico del acido 2,6-dimetil-3-metoxicarbonil-4-(2'-nitrofenil)-1,4-dihidropiri- din-5-carboxilico.
PT69763A (de) Substituierte aminoalkansauren und ihre herstellung
DE68902627D1 (de) Verwendung von chromanderivaten zur herstellung eines medikamentes zur behandlung von depressiven zustaenden.
JPS5655397A (en) Aminobenzoic acid ester derivative, and physiologically active agent containing said derivative
FR2380272A1 (fr) Derives de la coumarine et d'indane-diode, utilisables comme medicament
FR2453182A1 (fr) Procede de preparation d'un acide ursodesoxycholique de grande purete
GB939941A (en) Improvements in or relating to the manufacture of derivatives of 5-nitrofuran
FR2395250A1 (fr) Derives des acides amino- du guanidino-phenylpropioniques

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application